Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production

Ying Ying Tsai, William E. Rainey, Wendy B Bollag

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Aldosterone, secreted by the adrenal zona glomerulosa, enhances sodium retention, thus increasing blood volume and pressure. Excessive production of aldosterone results in high blood pressure and contributes to cardiovascular and renal disease, stroke and visual loss. Hypertension is also associated with obesity, which is correlated with other serious health risks as well. Although weight gain is associated with increased blood pressure, the mechanism by which excess fat deposits increase blood pressure remains unclear. Several studies have suggested that aldosterone levels are elevated with obesity and may represent a link between obesity and hypertension. In addition to hypertension, obese patients typically have dyslipidemia, including elevated serum levels of very low-density lipoprotein (VLDL). VLDL, which functions to transport triglycerides from the liver to peripheral tissues, has been demonstrated to stimulate aldosterone production. Recent studies suggest that the signaling pathways activated by VLDL are similar to those utilized by AngII. Thus, VLDL increases cytosolic calcium levels and stimulates phospholipase D (PLD) activity to result in the induction of steroidogenic acute regulatory (StAR) protein and aldosterone synthase (CYP11B2) expression. These effects seem to be mediated by the ability of VLDL to increase the phosphorylation (activation) of their regulatory transcription factors, such as the cAMP response element-binding (CREB) protein family of transcription factors. Thus, research into the pathways by which VLDL stimulates aldosterone production may identify novel targets for the development of therapies for the treatment of hypertension, particularly those associated with obesity, and other aldosterone-modulated pathologies.

Original languageEnglish (US)
Pages (from-to)R115-R129
JournalJournal of Endocrinology
Volume232
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

VLDL Lipoproteins
Aldosterone
Hypertension
Obesity
Cytochrome P-450 CYP11B2
Zona Glomerulosa
Blood Pressure
Transcription Factors
Cyclic AMP Response Element-Binding Protein
Phospholipase D
Dyslipidemias
Blood Volume
Weight Gain
Triglycerides
Cardiovascular Diseases
Sodium
Stroke
Fats
Phosphorylation
Pathology

Keywords

  • Adrenal cortex
  • Hypertension
  • Intracellular signalling
  • Obesity
  • Phosphorylation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production. / Tsai, Ying Ying; Rainey, William E.; Bollag, Wendy B.

In: Journal of Endocrinology, Vol. 232, No. 2, 01.01.2017, p. R115-R129.

Research output: Contribution to journalReview article

Tsai, Ying Ying ; Rainey, William E. ; Bollag, Wendy B. / Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production. In: Journal of Endocrinology. 2017 ; Vol. 232, No. 2. pp. R115-R129.
@article{5d86d3e0aa4745a5bfeca704d6c0c6bb,
title = "Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production",
abstract = "Aldosterone, secreted by the adrenal zona glomerulosa, enhances sodium retention, thus increasing blood volume and pressure. Excessive production of aldosterone results in high blood pressure and contributes to cardiovascular and renal disease, stroke and visual loss. Hypertension is also associated with obesity, which is correlated with other serious health risks as well. Although weight gain is associated with increased blood pressure, the mechanism by which excess fat deposits increase blood pressure remains unclear. Several studies have suggested that aldosterone levels are elevated with obesity and may represent a link between obesity and hypertension. In addition to hypertension, obese patients typically have dyslipidemia, including elevated serum levels of very low-density lipoprotein (VLDL). VLDL, which functions to transport triglycerides from the liver to peripheral tissues, has been demonstrated to stimulate aldosterone production. Recent studies suggest that the signaling pathways activated by VLDL are similar to those utilized by AngII. Thus, VLDL increases cytosolic calcium levels and stimulates phospholipase D (PLD) activity to result in the induction of steroidogenic acute regulatory (StAR) protein and aldosterone synthase (CYP11B2) expression. These effects seem to be mediated by the ability of VLDL to increase the phosphorylation (activation) of their regulatory transcription factors, such as the cAMP response element-binding (CREB) protein family of transcription factors. Thus, research into the pathways by which VLDL stimulates aldosterone production may identify novel targets for the development of therapies for the treatment of hypertension, particularly those associated with obesity, and other aldosterone-modulated pathologies.",
keywords = "Adrenal cortex, Hypertension, Intracellular signalling, Obesity, Phosphorylation",
author = "Tsai, {Ying Ying} and Rainey, {William E.} and Bollag, {Wendy B}",
year = "2017",
month = "1",
day = "1",
doi = "10.1530/JOE-16-0237",
language = "English (US)",
volume = "232",
pages = "R115--R129",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "2",

}

TY - JOUR

T1 - Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production

AU - Tsai, Ying Ying

AU - Rainey, William E.

AU - Bollag, Wendy B

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Aldosterone, secreted by the adrenal zona glomerulosa, enhances sodium retention, thus increasing blood volume and pressure. Excessive production of aldosterone results in high blood pressure and contributes to cardiovascular and renal disease, stroke and visual loss. Hypertension is also associated with obesity, which is correlated with other serious health risks as well. Although weight gain is associated with increased blood pressure, the mechanism by which excess fat deposits increase blood pressure remains unclear. Several studies have suggested that aldosterone levels are elevated with obesity and may represent a link between obesity and hypertension. In addition to hypertension, obese patients typically have dyslipidemia, including elevated serum levels of very low-density lipoprotein (VLDL). VLDL, which functions to transport triglycerides from the liver to peripheral tissues, has been demonstrated to stimulate aldosterone production. Recent studies suggest that the signaling pathways activated by VLDL are similar to those utilized by AngII. Thus, VLDL increases cytosolic calcium levels and stimulates phospholipase D (PLD) activity to result in the induction of steroidogenic acute regulatory (StAR) protein and aldosterone synthase (CYP11B2) expression. These effects seem to be mediated by the ability of VLDL to increase the phosphorylation (activation) of their regulatory transcription factors, such as the cAMP response element-binding (CREB) protein family of transcription factors. Thus, research into the pathways by which VLDL stimulates aldosterone production may identify novel targets for the development of therapies for the treatment of hypertension, particularly those associated with obesity, and other aldosterone-modulated pathologies.

AB - Aldosterone, secreted by the adrenal zona glomerulosa, enhances sodium retention, thus increasing blood volume and pressure. Excessive production of aldosterone results in high blood pressure and contributes to cardiovascular and renal disease, stroke and visual loss. Hypertension is also associated with obesity, which is correlated with other serious health risks as well. Although weight gain is associated with increased blood pressure, the mechanism by which excess fat deposits increase blood pressure remains unclear. Several studies have suggested that aldosterone levels are elevated with obesity and may represent a link between obesity and hypertension. In addition to hypertension, obese patients typically have dyslipidemia, including elevated serum levels of very low-density lipoprotein (VLDL). VLDL, which functions to transport triglycerides from the liver to peripheral tissues, has been demonstrated to stimulate aldosterone production. Recent studies suggest that the signaling pathways activated by VLDL are similar to those utilized by AngII. Thus, VLDL increases cytosolic calcium levels and stimulates phospholipase D (PLD) activity to result in the induction of steroidogenic acute regulatory (StAR) protein and aldosterone synthase (CYP11B2) expression. These effects seem to be mediated by the ability of VLDL to increase the phosphorylation (activation) of their regulatory transcription factors, such as the cAMP response element-binding (CREB) protein family of transcription factors. Thus, research into the pathways by which VLDL stimulates aldosterone production may identify novel targets for the development of therapies for the treatment of hypertension, particularly those associated with obesity, and other aldosterone-modulated pathologies.

KW - Adrenal cortex

KW - Hypertension

KW - Intracellular signalling

KW - Obesity

KW - Phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=85011961313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011961313&partnerID=8YFLogxK

U2 - 10.1530/JOE-16-0237

DO - 10.1530/JOE-16-0237

M3 - Review article

C2 - 27913572

AN - SCOPUS:85011961313

VL - 232

SP - R115-R129

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 2

ER -